Active ingredientElinzanetantCat. No. P-E023-001CAS 929046-33-3Family · Pharmaceutical analytical standards
Elinzanetant
A first-in-class antagonist of the neurokinin NK1 and NK3 receptors: it is a non-hormonal treatment for menopausal hot flushes, first approved in the United Kingdom in July 2025 and then in the United States and the European Union. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Before becoming a menopause medicine it was studied for schizophrenia, a research programme that was later discontinued.
Go to the active ingredient →Active ingredientElinzanetantCat. No. P-E023-001CAS 929046-33-3
Isotopically labelledElinzanetant-d6Cat. No. P-E023-002
ImpurityElinzanetant Enantiomer ImpurityCat. No. P-E023-009CAS 929047-01-8
ImpurityElinzanetant Impurity 1Cat. No. P-E023-010CAS 1268364-46-0
ImpurityElinzanetant Impurity 2Cat. No. P-E023-011CAS 1268446-43-0
ImpurityElinzanetant Impurity 3Cat. No. P-E023-012CAS 825643-73-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.